<DOC>
	<DOC>NCT02744222</DOC>
	<brief_summary>International multi-center double-blind comparative randomized clinical trial to evaluate efficacy, safety and tolerance of BCD-054 (JSC "BIOCAD", Russia) 120 mcg or 180 mcg intramuscularly, biweekly and Avonex® (Biogen Idec Limited, Great Britain) 30 mcg, weekly, for treatment of patients with remitting multiple sclerosis</brief_summary>
	<brief_title>Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Written informed consent Diagnosis of remitting multiple sclerosis according to McDonald criteria (2010) Minimum 1 relapse during last 12 months prior to screening Minimum 1 focus in brain that accumulates gadolinium (T1weighted images) or 1 new focus (T2weighted images) Patient has stable neurological state during last 30 days prior to screening EDSS score from 0 to 4,5 Secondary progressive and primary progressive forms of MS Other diseases that could influence course of the disease or symptoms assessment Relapse on screening or before 1 study drug injection History of use: interferon beta1a, interferon beta 1b, glatiramer acetate during last 30 days prior to randomization, monoclonal antibodies, cytotoxic or immunosuppressive drugs last 6 months prior to randomization, Use of corticosteroids intravenously or orally last 30 days prior to randomization. Intolerance or allergy to interferon beta or other excipients of BCD054 or Avonex® or pegylated proteins Full list of inclusion and exclusion criteria can be found in Protocol of the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>